
Brief intro:
- Author: Mateusz Imiolek, Szabolcs Fekete, Matthew A. Lauber
Products/Services used in the paper
Quotation shows PackGene:PackGene™ Firefly Luciferase-mRNA (Cap 1+N1meψUTP, SM-102, nominal mRNA concentration 0.2 mg/mL) LNPs were used.
Research Field:Size Exclusion, Chromatography for LNP
Abstract
This application note discusses the use of a GTxResolve™ Premier BEH™ SEC 450 Å Column for the online deformulation of LNPs and size exclusion separation of the mRNA payload. Common detergent disruption protocols have been tested and found to lead to incomplete deformulation of the sample, as both intact LNPs and freed nucleic acids can be still observed in the SEC chromatograms. While pursuing alternative options, we discovered that a detergent and organic solvent could be applied as mobile phase additives to achieve complete disruption of intact LNP samples upon their injection into the LC system, thus removing the need for a sample preparation step. With the developed method, nucleic acid payloads can be effectively liberated from the lipid vehicle, size separated and quantified in a rapid and robust assay requiring only a minimal amount of sample. Such an assay provides instant insights into an otherwise challenging characterization of LNP payloads and is especially suitable to samples with multiple payloads important for emerging gene editing therapies.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
